---
title: "Darzalex (daratumumab) in multiple myeloma: Indication questions"
description: "Indication questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: What is Darzalex Faspro approved for in multiple myeloma? What is Darzalex (daratumumab) IV approved for? What is the generic name for Darzalex and Darzalex Faspro? Which Darzalex regimens are approved for newly diagnosed multiple myeloma? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Indication questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## Indication

<a id="darzalex-faspro-indications"></a>

### What is Darzalex Faspro approved for in multiple myeloma?

> “DARZALEX FASPRO is indicated for the treatment of adult patients with [see 
> Clinical Studies (14)]:
> •	 multiple myeloma in combination with bortezomib, lenalidomide, and 
> dexamethasone for induction and consolidation in newly diagnosed 
> patients who are eligible for autologous stem cell transplant.
> •	 multiple myeloma in combination with bortezomib, lenalidomide, and 
> dexamethasone in newly diagnosed patients who are ineligible for 
> autologous stem cell transplant.
> •	 multiple myeloma in combination with bortezomib, melphalan and 
> prednisone in newly diagnosed patients who are ineligible for autologous 
> stem cell transplant.
> •	 multiple myeloma in combination with lenalidomide and dexamethasone 
> in newly diagnosed patients who are ineligible for autologous stem cell 
> transplant and in patients with relapsed or refractory multiple myeloma 
> who have received at least one prior therapy.
> •	 multiple myeloma in combination with bortezomib, thalidomide, and 
> dexamethasone in newly diagnosed patients who are eligible for 
> autologous stem cell transplant.
> •	 multiple myeloma in combination with bortezomib and dexamethasone in 
> patients who have received at least one prior therapy.
> •	 multiple myeloma in combination with pomalidomide and dexamethasone 
> in patients who have received at least one prior line of therapy including 
> lenalidomide and a proteasome inhibitor.
> •	 multiple myeloma in combination with carfilzomib and dexamethasone in 
> patients with relapsed or refractory multiple myeloma who have received 
> one to three prior lines of therapy.
> •	 multiple myeloma as monotherapy, in patients who have received at least 
> three prior lines of therapy including a proteasome inhibitor (PI) and an 
> immunomodulatory agent or who are double-refractory to a PI and an 
> immunomodulatory agent.
> 1.2	 High-Risk Smoldering Multiple Myeloma 
> DARZALEX FASPRO as monotherapy is indicated for the treatment of adult 
> patients with high-risk smoldering multiple myeloma.”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

Note: The label also lists newly diagnosed light chain (AL) amyloidosis, in combination with bortezomib, cyclophosphamide, and dexamethasone.

<a id="darzalex-iv-indications"></a>

### What is Darzalex (daratumumab) IV approved for?

> “DARZALEX is indicated for the treatment of adult patients with multiple 
> myeloma:
> •	 in combination with lenalidomide and dexamethasone in newly diagnosed 
> patients who are ineligible for autologous stem cell transplant and in 
> patients with relapsed or refractory multiple myeloma who have received 
> at least one prior therapy.
> •	 in combination with bortezomib, melphalan and prednisone in newly 
> diagnosed patients who are ineligible for autologous stem cell transplant.
> •	 in combination with bortezomib, thalidomide, and dexamethasone in newly 
> diagnosed patients who are eligible for autologous stem cell transplant.
> •	 in combination with bortezomib and dexamethasone in patients who have 
> received at least one prior therapy.
> •	 in combination with carfilzomib and dexamethasone in patients with 
> relapsed or refractory multiple myeloma who have received one to three 
> prior lines of therapy.
> •	 in combination with pomalidomide and dexamethasone in patients who 
> have received at least two prior therapies including lenalidomide and a 
> proteasome inhibitor.
> •	 as monotherapy, in patients who have received at least three prior lines 
> of therapy including a proteasome inhibitor (PI) and an immunomodulatory 
> agent or who are double-refractory to a PI and an immunomodulatory agent.”

Source: [DARZALEX: DARZALEX®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=2)

<a id="darzalex-newly-diagnosed-regimens"></a>

### Which Darzalex regimens are approved for newly diagnosed multiple myeloma?

Applies to: Newly diagnosed multiple myeloma, transplant-eligible and transplant-ineligible

> “DARZALEX FASPRO<sup>®</sup> is indicated for the treatment of adult patients with newly diagnosed multiple myeloma:
>
> Transplant eligible—in combination with VRd (induction and consolidation) and in combination with VTd<sup>1</sup>
> Transplant ineligible—in combination with Rd, VRd, or VMP<sup>1</sup>
>
> DARZALEX<sup>®</sup> is indicated for the treatment of adult patients with newly diagnosed multiple myeloma:
>
> Transplant eligible–in combination with VTd<sup>2</sup>
> Transplant ineligible–in combination with Rd or VMP<sup>2</sup>”

Source: [DARZALEX: FAQ, captured 2026-11-12](https://www.darzalexhcp.com/faq/#:~:text=with%20multiple%20myeloma%3F-,DARZALEX,ineligible%E2%80%93in%20combination%20with%20Rd%20or)

On the page, select: What daratumumab-based regimens are approved for newly diagnosed patients with multiple myeloma?

> “Rd=lenalidomide (R) + dexamethasone (d); VMP=bortezomib (V) + melphalan (M) + prednisone (P); VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d); VTd=bortezomib (V) + thalidomide (T) + dexamethasone (d).”

Source: [DARZALEX: FAQ, captured 2026-11-12](https://www.darzalexhcp.com/faq/#:~:text=Rd%3Dlenalidomide%20%28R%29%20%2B%20dexamethasone%20%28d%29%3B,thalidomide%20%28T%29%20%2B%20dexamethasone%20%28d%29.)

On the page, select: What daratumumab-based regimens are approved for newly diagnosed patients with multiple myeloma?

<a id="darzalex-perseus-maintenance"></a>

### Is Darzalex Faspro approved for maintenance therapy after transplant?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

> “multiple myeloma in combination with bortezomib, lenalidomide, and 
> dexamethasone for induction and consolidation in newly diagnosed 
> patients who are eligible for autologous stem cell transplant.”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

> “Following consolidation, 
> patients received an investigational treatment regimen for maintenance that 
> included DARZALEX FASPRO in combination with lenalidomide or lenalidomide 
> alone. The trial was not designed to isolate the effect of DARZALEX FASPRO 
> in the maintenance phase of treatment. The efficacy of DARZALEX FASPRO 
> in combination with lenalidomide for maintenance has not been established.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Table 4: DARZALEX FASPRO dosing schedule in combination with 
> bortezomib, lenalidomide and dexamethasone (4-week cycle)
> Treatment phase
> Weeks
> Schedule
> Induction
> Weeks 1 to 8
> weekly (total of 8 doses)
> Weeks 9 to 16<sup>a</sup>
> every two weeks (total of 4 doses)
> Stop for high dose chemotherapy and ASCT
> Consolidation
> Weeks 1 to 8<sup>b</sup>
> every two weeks (total of 4 doses)
> ª	 First dose of the every-2-week dosing schedule is given at Week 9
> <sup>b</sup>	 First dose of the every-2-week dosing schedule is given at Week 1 upon 
> re-initiation of treatment following ASCT”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

## Drug names

<a id="darzalex-generic-name"></a>

### What is the generic name for Darzalex and Darzalex Faspro?

> “DARZALEX<sup>®</sup> (daratumumab) injection, for intravenous use
> Initial U.S. Approval: 2015”

Source: [DARZALEX: DARZALEX®, page 1, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=1)

> “DARZALEX FASPRO<sup>®</sup> (daratumumab and hyaluronidase-fihj) injection, for 
> subcutaneous use
> Initial U.S. Approval: 2020”

Source: [DARZALEX: DARZALEX FASPRO®, page 1, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=1)

Note: Both passages are the title lines of the Prescribing Information: the first for DARZALEX, the second for DARZALEX FASPRO.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
